Search

Your search keyword '"Jornayvaz FR"' showing total 169 results

Search Constraints

Start Over You searched for: Author "Jornayvaz FR" Remove constraint Author: "Jornayvaz FR"
169 results on '"Jornayvaz FR"'

Search Results

1. Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

2. Stratégies diagnostiques des diarrhées chorniques de l'adulte

Catalog

Books, media, physical & digital resources

4. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.

7. Linking Antibodies Against Apolipoprotein A-1 to Metabolic Dysfunction-Associated Steatohepatitis in Mice.

8. Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric Oncology.

9. NADPH oxidases in healthy white adipose tissue and in obesity: function, regulation, and clinical implications.

10. Multi-omics correlates of insulin resistance and circadian parameters mapped directly from human serum.

11. Impact of an exercise program combined with dietary advice on avoiding insulin prescription in women with gestational diabetes: a randomized controlled trial.

12. Alterations of lipid homeostasis in morbid obese patients are partly reversed by bariatric surgery.

13. Langerhans cell histiocytosis of the suprasellar region: diagnosis based on thyroid cytology.

15. [Diabetic gastroparesis and type 1 diabetes].

16. [Obstetrics and Gynecology. Management and screening for gestational diabetes : what's new in 2023].

17. [Diabetology: what's new in 2023].

18. S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effects.

19. Circadian organization of lipid landscape is perturbed in type 2 diabetic patients.

20. Unnecessary thyroid surgery rate for suspicious nodule in the absence of molecular testing.

21. GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes.

22. The impact of transsphenoidal surgery on pituitary function in patients with non-functioning macroadenomas.

23. Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease.

24. [Non-Alcoholic Fatty Liver Disease and Diabetes: the bad marriage].

25. [The diabetic foot : a complex and multidisciplinary management].

28. [News in diabetology: what's new in 2022].

29. Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology.

30. Interleukin-18 in metabolism: From mice physiology to human diseases.

31. Circulating 1,5-Anhydroglucitol as a Biomarker of ß-cell Mass Independent of a Diabetes Phenotype in Human Subjects.

32. Canakinumab in patients with COVID-19 and type 2 diabetes - A multicentre, randomised, double-blind, placebo-controlled trial.

33. Effectiveness of Therapeutic Patient Education Interventions in Obesity and Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

34. Systematic Review and Meta-Analysis of the Usefulness of Epicardial Fat Thickness as a Non-Invasive Marker of the Presence and Severity of Nonalcoholic Fatty Liver Disease.

36. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.

37. Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days.

39. Hepatic non-parenchymal S100A9-TLR4-mTORC1 axis normalizes diabetic ketogenesis.

40. Sex-specific modulation of circulating growth differentiation factor-15 in patients with type 2 diabetes and/or obesity.

41. NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook.

42. [Diabetic neuropathy: an update].

43. [Insulin allergy: how to manage it?]

44. [Pancreatogenic Diabetes].

45. Growth differentiation factor-15 prevents glucotoxicity and connexin-36 downregulation in pancreatic beta-cells.

46. [News in diabetology 2021].

47. Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD.

48. Three Weeks Versus Six Weeks of Antibiotic Therapy for Diabetic Foot Osteomyelitis: A Prospective, Randomized, Noninferiority Pilot Trial.

49. [SGLT2 inhibitors : only beneficial ?]

50. [MODY type diabetes: an often-misunderstood entity].